Amy Larson, APRN
Family · Duluth, MNNPI 1639630478
Payments from drug & device makers
Across 20 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$86
- Galderma Laboratories, L.p.$52
- Lilly USA, LLC$42
- Teva Pharmaceuticals USA, Inc.$34
- Regeneron Healthcare Solutions, Inc.$32
- Amgen$31
- plus $120 from 6 others
What the payments were for
- Food & beverage$399100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $86 |
| Galderma Laboratories, L.p. | 2 | $52 |
| Lilly USA, LLC | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Amgen | 2 | $31 |
| Incyte Corporation | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
| UCB, Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
How this compares
$399 in reported general payments places this provider in the 80th percentile of 1,121 family providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 23 | $485,024 |
| Humira(Cf) PenAdalimumab | 11 | $152,555 |
| Dupixent SyringeDupilumab | 15 | $55,477 |
| Fluocinonide | 34 | $3,271 |
| Ketoconazole | 74 | $1,851 |
| Fluorouracil | 14 | $1,116 |
| Triamcinolone Acetonide | 116 | $1,091 |
| Metronidazole | 24 | $1,063 |
| Clobetasol Propionate | 30 | $777 |
| Clindamycin Phosphate | 22 | $662 |
| Doxycycline Monohydrate | 43 | $647 |
| Dutasteride | 13 | $575 |
| Mupirocin | 27 | $212 |
| Ciclopirox | 12 | $179 |
| Hydrocortisone | 25 | $151 |
Paid to pharmacies, not to this prescriber.
Other family in Duluth
- Kristina BormanDuluth$2K
- Erin HewittMinnetonka$172K
- Julia GourdeMinneapolis$65K
- Robin DontaMinneapolis$60K
- Kristin WeberMinneapolis$35K
- Crista WenischBurnsville$30K
- Kathleen FredellMinneapolis$28K
- Christina RichardsonNorthfield$27K
- Diana CzelMinneapolis$24K
- Alesya ShumkovMinnetonka$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.